Cargando…

Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era

PURPOSE: Survival after liver transplantation (LTX) has decreased in Germany since the implementation of Model for end-stage liver disease (MELD)-based liver allocation. Primary sclerosing cholangitis (PSC) is known for its otherwise excellent outcome after LTX. The influence of MELD-based liver all...

Descripción completa

Detalles Bibliográficos
Autores principales: Klose, Johannes, Klose, Michelle A., Metz, Courtney, Lehner, Frank, Manns, Michael P., Klempnauer, Juergen, Hoppe, Nils, Schrem, Harald, Kaltenborn, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232743/
https://www.ncbi.nlm.nih.gov/pubmed/24888532
http://dx.doi.org/10.1007/s00423-014-1214-6
_version_ 1782344629142683648
author Klose, Johannes
Klose, Michelle A.
Metz, Courtney
Lehner, Frank
Manns, Michael P.
Klempnauer, Juergen
Hoppe, Nils
Schrem, Harald
Kaltenborn, Alexander
author_facet Klose, Johannes
Klose, Michelle A.
Metz, Courtney
Lehner, Frank
Manns, Michael P.
Klempnauer, Juergen
Hoppe, Nils
Schrem, Harald
Kaltenborn, Alexander
author_sort Klose, Johannes
collection PubMed
description PURPOSE: Survival after liver transplantation (LTX) has decreased in Germany since the implementation of Model for end-stage liver disease (MELD)-based liver allocation. Primary sclerosing cholangitis (PSC) is known for its otherwise excellent outcome after LTX. The influence of MELD-based liver allocation and subsequent allocation policy alterations on the outcome of LTX for PSC is analyzed. METHODS: This is a retrospective observational study including 126 consecutive patients treated with LTX for PSC between January 1, 1999 and August 31, 2012. The PSC cohort was further compared to all other indications for LTX in the study period (n = 1420) with a mean follow-up of 7.9 years (SD 3.2). Multivariate risk-adjusted analyses were performed. Alterations of allocation policy have been taken into account systematically. RESULTS: Transplant recipients suffering from PSC are significantly younger (p < 0.001), can be discharged earlier (p = 0.018), and have lower 3-month mortality than patients with other indications (p = 0.044). The observed time on the waiting list is significantly longer for patients with PSC (p < 0.001), and there is a trend toward lower match MELD points in the PSC cohort (p = 0.052). No improvement in means of short-term mortality could be shown in relation to alterations of allocation policy within the MELD era (p = 0.375). Survival rates of the pre-MELD era did not differ significantly from those of the MELD era (p = 0.097) in multivariate risk-adjusted analysis. Patients in the MELD era suffered pre-transplant significantly more frequently from dominant bile duct stenosis (p = 0.071, p = 0.059, p = 0.048, respectively; chi(2)). CONCLUSIONS: Progress is stagnating in LTX for PSC. Current liver allocation for PSC patients should be reconsidered.
format Online
Article
Text
id pubmed-4232743
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-42327432014-11-18 Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era Klose, Johannes Klose, Michelle A. Metz, Courtney Lehner, Frank Manns, Michael P. Klempnauer, Juergen Hoppe, Nils Schrem, Harald Kaltenborn, Alexander Langenbecks Arch Surg Original Article PURPOSE: Survival after liver transplantation (LTX) has decreased in Germany since the implementation of Model for end-stage liver disease (MELD)-based liver allocation. Primary sclerosing cholangitis (PSC) is known for its otherwise excellent outcome after LTX. The influence of MELD-based liver allocation and subsequent allocation policy alterations on the outcome of LTX for PSC is analyzed. METHODS: This is a retrospective observational study including 126 consecutive patients treated with LTX for PSC between January 1, 1999 and August 31, 2012. The PSC cohort was further compared to all other indications for LTX in the study period (n = 1420) with a mean follow-up of 7.9 years (SD 3.2). Multivariate risk-adjusted analyses were performed. Alterations of allocation policy have been taken into account systematically. RESULTS: Transplant recipients suffering from PSC are significantly younger (p < 0.001), can be discharged earlier (p = 0.018), and have lower 3-month mortality than patients with other indications (p = 0.044). The observed time on the waiting list is significantly longer for patients with PSC (p < 0.001), and there is a trend toward lower match MELD points in the PSC cohort (p = 0.052). No improvement in means of short-term mortality could be shown in relation to alterations of allocation policy within the MELD era (p = 0.375). Survival rates of the pre-MELD era did not differ significantly from those of the MELD era (p = 0.097) in multivariate risk-adjusted analysis. Patients in the MELD era suffered pre-transplant significantly more frequently from dominant bile duct stenosis (p = 0.071, p = 0.059, p = 0.048, respectively; chi(2)). CONCLUSIONS: Progress is stagnating in LTX for PSC. Current liver allocation for PSC patients should be reconsidered. Springer Berlin Heidelberg 2014-06-04 2014 /pmc/articles/PMC4232743/ /pubmed/24888532 http://dx.doi.org/10.1007/s00423-014-1214-6 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Klose, Johannes
Klose, Michelle A.
Metz, Courtney
Lehner, Frank
Manns, Michael P.
Klempnauer, Juergen
Hoppe, Nils
Schrem, Harald
Kaltenborn, Alexander
Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
title Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
title_full Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
title_fullStr Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
title_full_unstemmed Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
title_short Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
title_sort outcome stagnation of liver transplantation for primary sclerosing cholangitis in the model for end-stage liver disease era
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232743/
https://www.ncbi.nlm.nih.gov/pubmed/24888532
http://dx.doi.org/10.1007/s00423-014-1214-6
work_keys_str_mv AT klosejohannes outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT klosemichellea outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT metzcourtney outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT lehnerfrank outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT mannsmichaelp outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT klempnauerjuergen outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT hoppenils outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT schremharald outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera
AT kaltenbornalexander outcomestagnationoflivertransplantationforprimarysclerosingcholangitisinthemodelforendstageliverdiseaseera